NeuroOne Medical Tech Q2 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $1.38M Up From $466.18K YoY
Portfolio Pulse from Benzinga Newsdesk
NeuroOne Medical Technologies (NMTC) reported Q2 2024 earnings with a GAAP EPS of $(0.11), missing the $(0.08) estimate by 37.5%. Year-over-year, the company saw a 10% increase in losses but a 195.38% increase in sales, reaching $1.38M up from $466.18K.
May 14, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NeuroOne Medical Technologies reported a larger-than-expected loss per share but showed significant sales growth in Q2 2024.
The missed EPS estimate could negatively impact investor sentiment in the short term, suggesting a potential decrease in stock price. However, the substantial increase in sales indicates strong business growth, which could counterbalance the negative impact of the earnings miss. Given these mixed signals, the short-term impact on NMTC's stock price is uncertain, leading to a neutral score.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100